ERBB2 and breast carcinoma: The effective inhibition of both mutated‐PI3Kα and enriched‐HER2 offers therapeutic potential to address multiple detrimental factors to improve outcomes for advanced HER2+ breast cancer patients; meanwhile, anti‐HER2 treatment‐naïve patients would not be necessary to receive PI3Kα‐targeted treatment.